drugset / Trial / NCT00003924

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

NCT00003924

Phase 3 Unknown 360 enrolled Lymphoma Study Association
RandomizedTreatment

Summary

RATIONALE: Interferon-alfa may interfere with the growth of cancer cells. Giving interferon-alfa following chemotherapy and peripheral stem cell transplantation may be an effective treatment for Hodgkin's disease or non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to determine the effectiveness of interferon alfa-2b following chemotherapy and stem cell transplantation in treating patients who have recurrent or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

Timeline

Start
1995-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject interferon alfa-2b Protein / enzyme biologic Subcutaneous

Indications